In recent decades, emerging infectious diseases have become one of the most serious challenges to global health. Climate change, deforestation, intensive agricultural expansion, urban overcrowding, antimicrobial resistance, and rapid international travel facilitate the emergence and spread of new pathogens. Below are ten of the most dangerous newly discovered or re-emerging diseases, with an overview of their pathophysiology, clinical picture, and global impact.<\/p>\n
COVID-19 is caused by the SARS-CoV-2 virus (a novel coronavirus), first identified in 2019. The virus primarily affects the respiratory epithelium by binding to ACE2 receptors, though it can damage almost every organ system. Clinical manifestations range from asymptomatic infection to severe viral pneumonia, Acute Respiratory Distress Syndrome (ARDS), thromboembolic complications, myocarditis, and multi-organ failure. Of particular note is “Long COVID,” characterized by persistent fatigue, cognitive dysfunction, shortness of breath, and cardiovascular symptoms that last for months after the acute infection. While vaccines have significantly reduced mortality and the number of severe cases, viral mutations continue to produce new variants with altered transmissibility and the potential for immune evasion.<\/p>\n
Strategic Risks:<\/b> High transmissibility, systemic inflammatory response, prothrombotic state, and long-term complications.<\/p>\n<\/li>\n<\/ul>\n2. Ebola Virus Disease (EVD)<\/h4>\n
Ebola is a severe viral hemorrhagic fever caused by filoviruses. After an incubation period of 2\u201321 days, patients develop high fever, severe weakness, myalgia, vomiting, and diarrhea, followed by bleeding, hypotensive shock, and multi-organ failure. Endothelial damage and cytokine storm are central to its pathophysiology. Mortality rates can reach 50\u201390%, and survivors may suffer long-term effects such as uveitis, joint pain, and fatigue. Outbreaks are unpredictable and often devastate weak healthcare systems.<\/p>\n
Strategic Risks:<\/b> Extremely high lethality and unpredictability of outbreaks.<\/p>\n<\/li>\n<\/ul>\n3. Marburg Virus Disease<\/h4>\n
The Marburg virus is closely related to Ebola and causes sudden fever, chills, headache, myalgia, and vomiting. Disease progression includes hemorrhagic manifestations, liver and kidney failure, shock, and frequently, death. Immune dysregulation and vascular damage are key features. Mortality rates can exceed 80%. No widely available vaccine exists, and outbreaks can occur in both rural and urban settings.<\/p>\n
Strategic Risks:<\/b> Extreme virulence, high mortality, and high potential for transmission to medical personnel.<\/p>\n<\/li>\n<\/ul>\n4. Nipah Virus Infection<\/h4>\n
Nipah virus, a zoonotic paramyxovirus, spreads from fruit bats and sometimes pigs to humans. Initial symptoms include fever, headache, dizziness, and myalgia, progressing to encephalitis, seizures, altered consciousness, and coma. Severe respiratory symptoms may also coexist. The mortality rate is 40\u201375%, and survivors often suffer from permanent neurological deficits. Human-to-human transmission has been documented in hospital and family settings. There is no approved antiviral therapy.<\/p>\n
Strategic Risks:<\/b> High mortality, neurological damage, and pandemic potential.<\/p>\n<\/li>\n<\/ul>\n5. Middle East Respiratory Syndrome (MERS)<\/h4>\n
MERS, caused by a coronavirus transmitted from dromedary camels, causes fever, cough, and severe pneumonia, often progressing to ARDS, kidney failure, and multi-organ dysfunction. The case-fatality rate is approximately 35%. Outbreaks are often linked to healthcare facilities, highlighting challenges in infection control. Zoonotic reservoirs and limited vaccine availability maintain a constant threat.<\/p>\n
Strategic Risks:<\/b> Severe clinical course with high lethality and nosocomial (hospital) spread.<\/p>\n<\/li>\n<\/ul>\n6. Mpox (Monkeypox)<\/h4>\n
Mpox is caused by an orthopoxvirus. The infection begins with fever, lymphadenopathy, and weakness, followed by a vesiculopustular rash. Although the disease is generally self-limiting, severe forms occur in immunocompromised patients. The 2022\u20132023 outbreak demonstrated sustained human-to-human transmission outside endemic regions in Africa, raising concerns about viral adaptation and global spread.<\/p>\n
Strategic Risks:<\/b> Spread driven by globalization and complications in vulnerable groups.<\/p>\n<\/li>\n<\/ul>\n7. Severe Fever with Thrombocytopenia Syndrome (SFTS)<\/h4>\n
SFTS is a tick-borne bunyavirus infection primarily recorded in East Asia. It manifests with fever, gastrointestinal symptoms, thrombocytopenia, leukopenia, and multi-organ dysfunction. In severe cases, bleeding and shock develop. The mortality rate is 10\u201330%. The geographic range of the disease is expanding due to climate change affecting tick habitats. Rare cases of human-to-human transmission via contact with blood have been recorded.<\/p>\n
Strategic Risks:<\/b> Climate-driven expansion, high mortality, and occupational risk.<\/p>\n<\/li>\n<\/ul>\n8. Candida auris Infection<\/h4>\n
Candida auris<\/i> is a multidrug-resistant fungal pathogen first identified in 2009 and now found on all continents. It causes bloodstream infections, wound infections, and otitis, mainly in hospitalized or immunocompromised patients. Key Issues:<\/b><\/p>\n Resistant to multiple classes of antifungals (azoles, echinocandins, amphotericin B).<\/p>\n<\/li>\n Can persist on surfaces for weeks, leading to hospital outbreaks.<\/p>\n<\/li>\n Often misidentified, which delays treatment. Unlike viral epidemics, C. auris<\/i> spreads silently in intensive care units, representing a “chronic pandemic” threat.<\/p>\n<\/li>\n Strategic Risks:<\/b> Multidrug resistance, potential for ICU outbreaks, and systemic disruption of healthcare.<\/p>\n<\/li>\n<\/ul>\n While malaria is an ancient disease, partial resistance to artemisinin-based combination therapies in Rwanda and Uganda represents a new global threat. Malaria caused by Plasmodium falciparum<\/i> kills hundreds of thousands of people annually, mostly children under five. Resistance could nullify decades of progress in reducing mortality. Clinical outcomes include severe anemia, cerebral malaria, multi-organ failure, and death.<\/p>\n Strategic Risks:<\/b> Therapeutic collapse in vulnerable regions and long-term setbacks for global health.<\/p>\n<\/li>\n<\/ul>\n Multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) tuberculosis continue to spread worldwide. It primarily affects the lungs but can cause disseminated disease. Symptoms include chronic cough, hemoptysis (bloody cough), fever, night sweats, and weight loss. Treatment is long, toxic, and expensive, and resistance threatens global goals to eliminate TB. Co-infection with HIV further increases morbidity and mortality.<\/p>\n Strategic Risks:<\/b> Chronic airborne transmission, treatment complexity, and potential for global spread.<\/p>\n<\/li>\n<\/ul>\n Past experiences show that healthcare systems are often collapsed by long-existing diseases that require only a slight change in their arsenal of pathognomonic properties. A seemingly insignificant modified version of a pathogen can cause immense damage to global healthcare systems, including Georgia’s, through:<\/p>\n Healthcare System Overload:<\/b> Sudden outbreaks of high-lethality viruses can quickly exceed hospital capacities.<\/p>\n<\/li>\n Therapeutic Limitations:<\/b> Drug resistance reduces treatment options, making the process more difficult and expensive.<\/p>\n<\/li>\n Surveillance and Early Detection Gaps:<\/b> Weak monitoring allows pathogens to spread unnoticed to epidemic scales.<\/p>\n<\/li>\n Economic and Social Disruption:<\/b> Diseases hinder economies, trade, and education.<\/p>\n<\/li>\n Equality and Accessibility Issues:<\/b> Vulnerable populations in low-resource regions are disproportionately affected.<\/p>\n<\/li>\n<\/ul>\n Essentially, these diseases highlight the need for robust global preparedness, including rapid diagnostics, universal vaccination strategies, and interstate cooperation.<\/p>\n","protected":false},"excerpt":{"rendered":" In recent decades, emerging infectious diseases have become one of the most serious challenges to global health. Climate change, deforestation, intensive agricultural expansion, urban overcrowding, antimicrobial resistance, and rapid international travel facilitate the emergence and spread of new pathogens. Below are ten of the most dangerous newly discovered or re-emerging diseases, with an overview of […]<\/p>\n","protected":false},"author":28,"featured_media":14321,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1594],"tags":[],"class_list":["post-14320","post","type-post","status-publish","format-standard","has-post-thumbnail","category-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/14320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/comments?post=14320"}],"version-history":[{"count":4,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/14320\/revisions"}],"predecessor-version":[{"id":14329,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/14320\/revisions\/14329"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media\/14321"}],"wp:attachment":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media?parent=14320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/categories?post=14320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/tags?post=14320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
9. Artemisinin-Resistant Malaria<\/h4>\n
\n
10. Antimicrobial-Resistant Tuberculosis<\/h4>\n
\n
\nFuture Challenges<\/h3>\n
\n